Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DL-LYSINE ACETYLSALICYLATE CRS (15 MG)

DL-LYSINE ACETYLSALICYLATE CRS (15 MG)

ND

DISCOVER
DL-LYSINE ACETYLSALICYLATE IMPURITY C CRS (5 MG)

DL-LYSINE ACETYLSALICYLATE IMPURITY C CRS (5 MG)

ND

DISCOVER
DL-LYSINE ACETYLSALICYLATE IMPURITY G CRS (15 MG)

DL-LYSINE ACETYLSALICYLATE IMPURITY G CRS (15 MG)

ND

DISCOVER
CELIPROLOL FOR SYSTEM SUITABILITY CRS (20 MG)

CELIPROLOL FOR SYSTEM SUITABILITY CRS (20 MG)

ND

DISCOVER
PRIMIDONE FOR SYSTEM SUITABILITY CRS (10 MG)

PRIMIDONE FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
BETIATIDE CRS (20 MG)

BETIATIDE CRS (20 MG)

ND

DISCOVER
BETIATIDE IMPURITY D CRS (10 MG)

BETIATIDE IMPURITY D CRS (10 MG)

ND

DISCOVER
LATANOPROST CRS (100 MG)

LATANOPROST CRS (100 MG)

130209-82-4

DISCOVER
FLUOXETINE HYDROCHLORIDE FOR ID AND ASSAY CRS (250 MG)

FLUOXETINE HYDROCHLORIDE FOR ID AND ASSAY CRS (250 MG)

ND

DISCOVER
MONOTROPEIN CRS (10 MG)

MONOTROPEIN CRS (10 MG)

ND

DISCOVER
TICAGRELOR IMPURITY E CRS (15MG)

TICAGRELOR IMPURITY E CRS (15MG)

ND

DISCOVER
TICAGRELOR CRS (120 MG)

TICAGRELOR CRS (120 MG)

ND

DISCOVER